ARCHIVES

Chabner, FDA’s Temple continue disagreement Over Drug Approval

This article is from The Cancer Letter archive.

Vol. 15 No. 06 | February 10, 1989

Download PDF Visit The Full Archive

Related Articles

IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies

May 8, 1987

Who Will Determine Pay Lines For Each Program at NCI? Upton Suggests A Collective Approach

February 17, 1978

Frozen Serum Panels Available For Assays

June 8, 1984

FDA Approves Evista for Breast Cancer Risk Reduction.

September 14, 2007

Canadian Products Anticancer Drugs In Plant Culture

April 22, 1983

“Triple-Negative” Should Be Split Into Subtypes, Say Researchers

February 22, 2013